ProVisors Member Thought Leadership

Latest from ProVisors Member Thought Leadership

Why “What Should I Delegate?” Is a Harder Question Than It Seems

For most business owners, the challenge isn’t knowing that they need support, or even the budget to afford it, but knowing where to start.
“What should I delegate?” sounds straightforward, but in practice, it is one of the more difficult decisions to make within an operating business. Not

AI money is moving at warp speed. If your legal house still looks like a prototype, that gap can be very dangerous.
Pitchbook’s recent North America–focused Q1 breakdown puts total seed and pre‑seed investment at roughly $5.1B, and both Pitchbook and other Q1 write‑ups suggest AI and adjacent startups are taking an outsized share of those early‑stage checks. The Q1

If month-end close feels like a fire drill every month, you are not alone. Many growing businesses are stuck in a cycle of late nights, manual spreadsheets, and financial reports that arrive weeks after the decisions they were meant to support.

At the same time, the accounting world is changing. Instead of hiring full-time executives before they are ready, more

Throw punches in bunches! Elbows in, you win! Where do you want to be – not there! Let your punches go with bad intentions! Jab, hook, cross! Move that head! Hit and don’t get hit! Keep your left up! Train hard! Set up those combinations! Win! Distance is everything. Bite down! Breathe! Yo, Adrian, I did it! Everything is off

Most businesses don’t struggle with strategy.
They struggle with execution.
Plans are created. Goals are discussed. Priorities are announced.
But somewhere between strategy and daily operations, momentum slows.
The organizations that consistently outperform are not always the ones with the boldest ideas.
They are the ones that turn direction into disciplined, repeatable action.
Activity Isn’t the Same as Progress
Many

The clinical landscape surrounding metabolic health and the rapidly growing field of restorative medicine is currently facing a fundamental transformation of an unprecedented scale. As of May 2026, the professional medical community is actively witnessing an undeniable, rapidly accelerating surge in patient demand specifically for various peptide-based therapies, a demand that has unequivocally moved far beyond the highly regulated, traditional